Podcast

At-Home Genetic Testing: Dispelling Fact vs Fiction

Author(s):

Kristie L. Kahl

This week, we spoke with FORCE to dispel some of the misconceptions associated with at-home genetic testing for hereditary cancer risk.

With the flood of information available on genetic testing for hereditary cancer risk, there is still an abundance of misinformation that exists regarding at-home tests.

Lisa Schlager, Vice President of Community Affairs and Public Policy at FORCE, helped to dispel some of the misconceptions associated with at-home genetic testing, and why it is still vital to include a genetic counselor in this process.

For more information, visit www.facingourrisk.org.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Image of woman.
Sue Friedman in an interview with CURE
Dr. Alex Francoeur interviewing against a gray CURE background
Related Content
Rendering of an ovary with a tumor
April 7th 2025

BELLA Clinical Trial Initiated in Platinum-Resistant Ovarian Cancer

Alex Biese
The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ovarian cancer has been launched.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Ovaries.
March 31st 2025

Relacorilant Plus Chemo Meets Primary Goal in Ovarian Cancer Trial

Spencer Feldman
The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ovarian cancer.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized: © Tada Images - stock.adobe.com
March 24th 2025

Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer

Alex Biese
The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory agencies.
Elahere shows consistent survival benefits in patients with folate receptor alpha-positive platinum-resistant ovarian cancer: ©mi_viri - stock.adobe.com.
March 17th 2025

Elahere Shows Consistent Survival Benefit in Ovarian Cancer Subset

Spencer Feldman
Elahere shows consistent survival benefits in patients with folate receptor alpha-positive platinum-resistant ovarian cancer in the MIRASOL trial.